Methods and materials: Patients with ongoing or planned anticancer treatment at 19 Italian Radiation Oncology centers were included in the study retrospectively from 3 February 2020 to 31 December 2020 and prospectively from 1 January 2021 to 31 May 2021. Anonymized data were processed through a specific website and database. Antineoplastic treatment characteristics and timing and outcomes of COVID-19 and its impact on radiotherapy or systemic therapy were described. Results: The retrieved cohort included 41,039 patients that received treatment or were planned for therapy in the study period. Overall, 123 patients had a confirmed COVID-19 diagnosis during antineoplastic treatment (group A) and 99 patients before treatment start (group B). The incidence of COVID-19 across the whole cohort in the index period was 0.54% (groups A + B) and 0.30% considering only group A. A total of 60 patients developed severe COVID-19, and a total of 45 patients died as a consequence of the infection (incidence of 0.15% and 0.11%, respectively). Nonetheless, mortality among COVID-19 patients was high, with an attributable death rate after confirmed infection of 20.27%. Among the 123 patients in group A, 37.4% required temporary treatment suspension, 32.5% definitive suspension and 37 patients continued treatment while positive. As for the 99 patients in group B, 53.5% experienced temporary delay, 20.2% experienced definitive treatment suspension and 26.3% had no delay. Conclusions: Most of the patients with a COVID-19 diagnosis in our cohort recovered and completed their treatment; nonetheless, the attributable death rate after confirmed infection was 20.27%, and mortality was high among cancer patients with severe COVID-19 presentation. The global incidence of death due to COVID-19 or severe COVID-19 was low and decreased over time. Radiation oncology activity could be safely continued during the COVID-19 pandemic with the adoption of adequate preventive measures.
方法与材料：本研究回顾性纳入2020年2月3日至2020年12月31日期间、前瞻性纳入2021年1月1日至2021年5月31日期间，在意大利19家放射肿瘤中心接受或计划接受抗癌治疗的患者。通过专用网站及数据库对匿名化数据进行处理。研究描述了抗肿瘤治疗特征、COVID-19感染时间与结局，及其对放疗或全身治疗的影响。结果：研究期间共纳入41,039例已接受或计划接受治疗的患者。其中123例患者在抗肿瘤治疗期间确诊COVID-19（A组），99例患者在治疗开始前确诊（B组）。整个队列在观察期内COVID-19总发病率为0.54%（A+B组），仅A组发病率为0.30%。共有60例患者发展为重症COVID-19，45例患者因感染死亡（发病率分别为0.15%和0.11%）。尽管如此，COVID-19患者死亡率较高，确诊感染后的归因死亡率达20.27%。在A组123例患者中，37.4%需要暂停治疗，32.5%永久终止治疗，37例患者在阳性期间继续治疗。B组99例患者中，53.5%出现治疗延迟，20.2%永久终止治疗，26.3%未受影响。结论：本队列中大多数确诊COVID-19的患者康复并完成治疗；然而确诊感染后的归因死亡率达20.27%，且出现重症COVID-19表现的癌症患者死亡率较高。因COVID-19或重症COVID-19导致的总体死亡率较低且随时间推移呈下降趋势。通过采取适当预防措施，放射肿瘤诊疗活动可在COVID-19大流行期间安全开展。
肿瘤(癌症)患者之家